Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

Clinical Trial Description

The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00373646
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	Phase 2
Start date	June 2006
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05003141` - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Phase 1
Completed	`NCT01015248` - Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	Phase 2
Completed	`NCT00201422` - Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma	N/A
Unknown status	`NCT00923663` - Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Phase 2
Completed	`NCT00783367` - Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas	Phase 2
Active, not recruiting	`NCT01808599` - Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma	Phase 2
Completed	`NCT00117156` - Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05544019` - Study of SGR-1505 in Mature B-Cell Neoplasms	Phase 1
Completed	`NCT00373906` - Velcade in MALT Lymphoma Patients	Phase 2